NEO 1940

Drug Profile

NEO 1940

Latest Information Update: 11 May 2016

Price : $50

At a glance

  • Originator NEOMED
  • Class Antiemetics; Appetite stimulants; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cachexia

Highest Development Phases

  • Phase I Cachexia; Cancer pain; Nausea and vomiting

Most Recent Events

  • 11 May 2016 Phase I development is ongoing in Canada
  • 30 Apr 2013 Therapeutic efficacy and adverse events data from a phase I trial in Cachexia, Cancer pain, Nausea and vomiting released by NEOMED
  • 30 Apr 2013 NEOMED plans a phase II trial for Cachexia, Cancer pain, Nausea and vomiting in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top